Follicular Lymphoma Cell Models for Research

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma worldwide, accounting for approximately 20-30% of all NHL cases. According to the World Health Organization (WHO) GLOBOCAN 2020 data, there were an estimated 544,352 new cases of non-Hodgkin lymphoma and 259,720 deaths globally. FL has a median age at diagnosis of 60-65 years, with a slight male predominance. The 5-year relative survival rate for FL is approximately 90% for localized disease (stage I-II) and 85% for advanced disease (stage III-IV), based on NCI SEER data. However, FL is generally incurable with conventional therapy, and patients often experience multiple relapses, with a median overall survival of 18-20 years. Transformation to diffuse large B-cell lymphoma (DLBCL) occurs at a rate of 2-3% per year and is associated with a poor prognosis. Key risk factors include immunosuppression, autoimmune diseases, and family history of lymphoma. The clinical heterogeneity and incurable nature of FL underscore the need for robust preclinical models to study disease mechanisms and develop novel therapies.

FL is an ideal model for mechanistic studies due to its well-defined genetic landscape, the availability of public datasets (e.g., TCGA, COSMIC), and the presence of both indolent and transformed phases. The hallmark t(14;18) translocation is present in 85-90% of FL cases, leading to BCL2 overexpression, but this alone is insufficient for tumorigenesis, indicating a need for secondary genetic events. FL also exhibits a unique tumor microenvironment with abundant T cells and follicular dendritic cells. Open questions include the role of epigenetic modifiers (e.g., EZH2, CREBBP, KMT2D) in disease progression, the mechanisms of immune evasion, and the drivers of histologic transformation. Gene-edited cell models allow researchers to dissect the contribution of specific mutations in a controlled isogenic background, providing a powerful tool to address these questions.

The pathogenesis of FL involves multiple interconnected pathways:

1. BCL2 overexpression: The t(14;18) translocation places BCL2 under the immunoglobulin heavy chain enhancer, leading to constitutive overexpression of the anti-apoptotic protein, preventing germinal center B-cell apoptosis.

2. Epigenetic dysregulation: Mutations in histone-modifying genes (EZH2, CREBBP, KMT2D, EP300) lead to aberrant chromatin remodeling, altering gene expression programs that promote survival and block differentiation.

3. Immune evasion: FL cells exploit the tumor microenvironment, including regulatory T cells and tumor-associated macrophages, to suppress anti-tumor immunity. Genetic alterations in B2M and CD58 can impair antigen presentation.

4. B-cell receptor (BCR) signaling: Chronic active BCR signaling, often driven by mutations in CARD11, MYD88, or CD79B, activates NF-κB and PI3K/AKT pathways, promoting proliferation and survival.

Data from TCGA (PanCancer Atlas) and COSMIC (v98).

Key signaling networks in FL include:

• • BCR/NF-κB pathway: Mutations in CARD11, MYD88, and CD79B lead to constitutive activation of NF-κB, promoting survival and proliferation.
• • PI3K/AKT/mTOR pathway: Frequently activated due to BCR signaling or PTEN loss, driving cell growth and metabolism.
• • JAK-STAT pathway: STAT6 mutations result in constitutive activation, promoting immune evasion and proliferation.
• • Epigenetic regulatory network: EZH2, CREBBP, and KMT2D mutations alter histone modifications, leading to aberrant gene silencing or activation.
• • Apoptosis regulation: BCL2 overexpression blocks the intrinsic apoptotic pathway, while TP53 mutations (in transformed FL) disrupt DNA damage response.
• • Immune checkpoint axis: PD-L1/PD-1 interactions are exploited by FL cells to evade T-cell-mediated killing.

Organoid models: 3D culture systems that recapitulate the FL tumor microenvironment, including follicular dendritic cells and T cells. They allow study of cell-cell interactions and drug responses in a more physiologically relevant context. However, they are technically challenging and have limited throughput compared to 2D cell lines.

Animal models for FL include:

• • Patient-derived xenografts (PDX): Engraftment of FL patient cells into immunodeficient mice (e.g., NSG). They preserve the genetic heterogeneity of the original tumor but have low engraftment rates and require human cytokine supplementation.
• • Genetically engineered mouse models (GEMM): VavP-Bcl2 mice overexpress BCL2 in B cells, developing follicular hyperplasia but not frank lymphoma. Crossing with other mutants (e.g., MYC, TP53) can accelerate tumorigenesis.
• • Induced models: Use of Cre-lox systems to conditionally express BCL2 and other oncogenes in germinal center B cells. For example, Cγ1-Cre; Bcl2-Tg mice develop FL-like disease.
• • Humanized mouse models: Engraftment of human immune cells to study interactions between FL cells and the immune system.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise genetic modifications, such as knockouts, knock-ins, and point mutations. These models are essential for studying the functional impact of specific FL-associated mutations in a controlled background. For example:

• • TP53 knockout: In FL cell lines, TP53 knockout models are used to study the role of p53 in response to DNA damage and chemotherapeutic agents.
• • EZH2 Y641N knock-in: This gain-of-function mutation is introduced into FL cell lines to study its effect on H3K27me3 levels and gene expression.
• • CREBBP knockout: Loss-of-function models help elucidate the role of histone acetylation in FL pathogenesis.
• • BCL2 overexpression: Knock-in of the t(14;18) translocation or BCL2 cDNA can be used to model the initiating event.

Commercially available, sequence-verified gene-edited cell lines (from sources such as those offering CRISPR services) provide researchers with ready-to-use tools, accelerating drug discovery and functional genomics studies. These models are validated for on-target editing and absence of off-target effects.

Gene-edited cells are used to validate the function of genes implicated in FL. For example:

• • CRISPR knockout of KMT2D in FL cell lines leads to altered H3K4 methylation and changes in gene expression, confirming its role as a tumor suppressor.
• • Knock-in of EZH2 Y641N mutation in a wild-type background increases H3K27me3 levels and promotes cell proliferation, demonstrating its oncogenic function.
• • Loss-of-function studies of TNFRSF14 reveal its role in immune evasion by modulating the tumor microenvironment.
• • CRISPR screens using pooled libraries can identify essential genes for FL survival, providing novel therapeutic targets.

Isogenic cell line pairs (e.g., wild-type vs. TP53 knockout) are used in high-throughput drug screens to identify compounds that selectively kill mutant cells. This approach helps in:

• • Identifying drugs that target specific genetic vulnerabilities (e.g., EZH2 inhibitors in EZH2-mutant cells).
• • Modeling acquired resistance: Chronic exposure of gene-edited cells to a drug can select for resistant clones, allowing the identification of resistance mechanisms.
• • Testing combination therapies: Gene-edited cells are used to evaluate synergistic effects of drugs targeting different pathways.
• • Example: An isogenic pair of FL cells with and without CREBBP knockout can be used to screen for compounds that are selectively toxic to CREBBP-deficient cells, mimicking the clinical response to HDAC inhibitors.

CRISPR-based synthetic lethality screens in FL cells can identify genes that, when knocked out, are lethal only in the presence of a specific mutation. For example:

• • In EZH2-mutant FL cells, knocking out ARID1A may be synthetically lethal, providing a potential therapeutic target.
• • Gene-edited cells are used to validate candidate biomarkers by correlating genetic alterations with drug sensitivity or resistance.
• • CRISPR screens can also identify genes involved in immune evasion, such as PD-L1 regulators, which can serve as biomarkers for immunotherapy response.